Potential Tumor Suppressor Role for the c-Myb Oncogene in Luminal Breast Cancer

Background The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60–80%). Methodology/Principal Findings We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. Stable RNAi knock-down of endogenous c-Myb in the MCF7 luminal breast tumor cell line increased tumorigenesis both in vitro and in vivo, suggesting a possible tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature, comprised of both direct and indirect c-Myb target genes, and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. Conclusions/Significance These data describe, for the first time, a possible tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for the understanding of luminal tumorigenesis and for guiding treatment.

[1]  B. Calabretta,et al.  Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[2]  C. Perou,et al.  In Vitro and In Vivo Analysis of B-Myb in Basal-Like Breast Cancer , 2008, Oncogene.

[3]  J M Trent,et al.  MYB oncogene amplification in hereditary BRCA1 breast cancer. , 2000, Cancer research.

[4]  K. Horwitz,et al.  Estrogen receptor positive breast cancer metastasis: altered hormonal sensitivity and tumor aggressiveness in lymphatic vessels and lymph nodes. , 2006, Cancer research.

[5]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[6]  Robert G. Ramsay,et al.  MYB function in normal and cancer cells , 2008, Nature Reviews Cancer.

[7]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[9]  S. Swerdlow,et al.  A functional c-myb gene is required for normal murine fetal hepatic hematopoiesis , 1991, Cell.

[10]  A. Gabrielli,et al.  Collagen loss and impaired wound healing is associated with c‐Myb deficiency , 2007, The Journal of pathology.

[11]  J. Bishop,et al.  Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: The architecture of a transduced oncogene , 1982, Cell.

[12]  K. Cowan,et al.  Posttranscriptional regulation of the c-myb proto-oncogene in estrogen receptor-positive breast cancer cells. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  H. Horlings,et al.  Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck , 2009, Proceedings of the National Academy of Sciences.

[14]  C. Perou,et al.  Cell-Type-Specific Responses to Chemotherapeutics in Breast Cancer , 2004, Cancer Research.

[15]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[16]  J. Rushton,et al.  Positive and Negative Determinants of Target Gene Specificity in Myb Transcription Factors*[boxs] , 2004, Journal of Biological Chemistry.

[17]  N Andrieu,et al.  Strong association between c-myb and oestrogen-receptor expression in human breast cancer. , 1990, Oncogene.

[18]  J. Malaterre,et al.  c‐Myb Is Required for Neural Progenitor Cell Proliferation and Maintenance of the Neural Stem Cell Niche in Adult Brain , 2008, Stem cells.

[19]  B. Calabretta,et al.  An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[20]  J. Lipsick,et al.  Myb proteins inhibit fibroblast transformation by v-Rel , 2006, Molecular Cancer.

[21]  A. Thorner,et al.  Mitochondrial HEP27 Is a c-Myb Target Gene That Inhibits Mdm2 and Stabilizes p53 , 2010, Molecular and Cellular Biology.

[22]  J. Rushton,et al.  Distinct changes in gene expression induced by A-Myb, B-Myb and c-Myb proteins , 2003, Oncogene.

[23]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[24]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[25]  D. Leprince,et al.  A putative second cell-derived oncogene of the avian leukaemia retrovirus E26 , 1983, Nature.

[26]  Simon C Barry,et al.  Mechanism of and requirement for estrogen-regulated MYB expression in estrogen-receptor-positive breast cancer cells , 2007, Proceedings of the National Academy of Sciences.

[27]  Zhiyuan Hu,et al.  Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Zon,et al.  In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[29]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[30]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[32]  K. Rajewsky,et al.  Critical functions for c-Myb at three checkpoints during thymocyte development , 2004, Nature Immunology.

[33]  B. Aronow,et al.  Diverse developing mouse lineages exhibit high-level c-Myb expression in immature cells and loss of expression upon differentiation , 1999, Oncogene.

[34]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[36]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Ishii,et al.  Inactivation of a c-Myb/estrogen receptor fusion protein in transformed primary cells leads to granulocyte/macrophage differentiation and down regulation of c-kit but not c-myc or cdc2 , 1997, Oncogene.

[38]  H. Clevers,et al.  c-Myb is required for progenitor cell homeostasis in colonic crypts , 2007, Proceedings of the National Academy of Sciences.

[39]  R. Strausberg,et al.  Mutation of GATA3 in human breast tumors , 2004, Oncogene.

[40]  I. D'Agnano,et al.  c-Myb and Bcl-x overexpression predicts poor prognosis in colorectal cancer: clinical and experimental findings. , 2001, The American journal of pathology.

[41]  A. Nobel,et al.  The molecular portraits of breast tumors are conserved across microarray platforms , 2006, BMC Genomics.

[42]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.